Patients with ibrutinib dose reduction after an AE had longer treatment length and similar efficacy versus no dose reduction. A study on patterns in patients with CLL found the RFC regimen appeared to be most effective for OS and response rates. Patients with chronic lymphocytic leukemia experience more anxiety when receiving intravenous versus oral treatments. Patients with CLL who relapsed after HSCT and then received venetoclax therapy achieved outcomes consistent with trial data.